Regeneron Announces Positive Topline Phase 2 Data with Anti -C5 Antibody Pozelimab in Patients with a Rare Blood Disorder

STL.News

(STL.News) – Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced topline data from the pozelimab (REGN3918) Phase 2 clinical program in paroxysmal nocturnal hemoglobinuria (PNH), validating the weekly 800 mg subcutaneous…

The post Regeneron Announces Positive Topline Phase 2 Data with Anti -C5 Antibody Pozelimab in Patients with a Rare Blood Disorder appeared first on STL News.

Source link